The trial included 30 kids with suspected or confirmed rabies exposure who were treated with KEDRAB (Rabies Immune Globulin [Human]) and followed for 84 days. KEDRAB was put into and around detectable wounds and/or given intramuscularly along.
Rabies treatment demonstrated as safe, effective for use in children in first pediatric trial ANI | Updated: Feb 10, 2021 12:09 IST
Washington [US], February 10 (ANI): A treatment, known as KEDRAB (Rabies Immune Globulin [Human]), currently used in the prevention of rabies has been demonstrated to be safe and effective for patients age 17 and under.
Results published today in Human Vaccines & Immunotherapeutics report the first and only pediatric trial of any human rabies immunoglobulin (HRIG) currently available in the US. Findings have been submitted to the US Food and Drug Administration for review.
In the United States, someone is treated for possible exposure to rabies every 10 minutes. Globally, the World Health Organization (WHO) estimates that rabies causes 59,000 human deaths annually in over 150 countries, with 95% of cases occurring in Africa and Asia - however, they concede it is likely a gross underestimate of the true burden of
E-Mail
A treatment, known as KEDRAB (Rabies Immune Globulin [Human]), currently used in the prevention of rabies has been demonstrated to be safe and effective for patients age 17 and under.
Results published today in
Human Vaccines & Immunotherapeutics report the first and only pediatric trial of any human rabies immunoglobulin (HRIG) currently available in the US. Findings have been submitted to the US Food and Drug Administration for review.
In the United States, someone is treated for possible exposure to rabies every 10 minutes. Globally, the World Health Organization (WHO) estimates that rabies causes 59,000 human deaths annually in over 150 countries, with 95% of cases occurring in Africa and Asia - however they concede it is likely a gross underestimate of the true burden of disease.
Rabies treatment, KEDRAB, demonstrated to be safe and effective in children
Results published today in
Human Vaccines & Immunotherapeutics report the first and only pediatric trial of any human rabies immunoglobulin (HRIG) currently available in the US. Findings have been submitted to the US Food and Drug Administration for review.
Close-up of a dog’s face during late-stage “dumb” paralytic rabies/CDC
In the United States, someone is treated for possible exposure to rabies every 10 minutes. Globally, the World Health Organization (WHO) estimates that rabies causes 59,000 human deaths annually in over 150 countries, with 95% of cases occurring in Africa and Asia – however they concede it is likely a gross underestimate of the true burden of disease.
Study on first pedriatic trial of rabies in children theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.